BCAR3 and BCAR3-related competing endogenous RNA expression in hepatocellular carcinoma and their prognostic value

Table 1 Association between BCAR3 expression and the clinical parameters in patients with hepatocellular carcinoma in The Cancer Genome Altas, n (%)

Characteristics	Low expression of BCAR3	High expression of BCAR3	P value
n	187	187
Gender			0.912
Male	127 (34)	126 (33.7)
Female	60 (16)	61 (16.3)
Age			0.275
≤ 60	94 (25.2)	83 (22.3)
> 60	93 (24.9)	103 (27.6)
Tumor status			0.014
Tumor free	111 (31.3)	91 (25.6)
With tumor	64 (18)	89 (25.1)
Pathologic T stage			0.085
T1 and T2	146 (39.4)	132 (35.6)
T3	37 (10)	43 (11.6)
T4	3 (0.8)	10 (2.7)
Pathologic M stage			0.667
M0	138 (50.7)	130 (47.8)
M1	3 (1.1)	1 (0.4)
AFP (ng/mL)			0.056
≤ 400	110 (39.3)	105 (37.5)
> 400	42 (15)	23 (8.2)
Histological type			0.996
Fibrolamellar carcinoma	1 (0.3)	2 (0.5)
Hepatocellular carcinoma	183 (49.9)	181 (49.3)
Overall survival event			0.017
Alive	133 (35.6)	111 (29.7)
Dead	54 (14.4)	76 (20.3)
Disease specific survival event			0.009
No	153 (41.8)	134 (36.6)
Yes	29 (7.9)	50 (13.7)
Progression free interval event			0.005
No	109 (29.1)	82 (21.9)
Yes	78 (20.9)	105 (28.1)

AFP: Alpha-fetoprotein.

Table 2 Univariate Cox regression and multivariate Cox regression analysis of prognosis-related risk factors in hepatocellular carcinoma

Characteristics	Total (N)	Univariate analysis		Multivariate analysis
		Hazard ratio (95%CI)	P value	Hazard ratio (95%CI)	P value
Pathological T stage	370		< 0.001
T1	183	Reference		Reference
T2	94	1.428 (0.901-2.264)	0.129	1.368 (0.846-2.212)	0.201
T3 and T4	93	2.949 (1.982-4.386)	< 0.001	2.458 (1.610-3.751)	< 0.001
Tumor status	354		< 0.001
Tumor free	202	Reference		Reference
With tumor	152	2.317 (1.590-3.376)	< 0.001	1.864 (1.261-2.755)	0.002
BCAR3	373		0.029
Low	187	Reference		Reference
High	186	1.472 (1.038-2.088)	0.030	1.245 (0.859-1.805)	0.247
Gender	373		0.204
Female	121	Reference
Male	252	0.793 (0.557-1.130)	0.200
Age	373		0.293
≤ 60	177	Reference
> 60	196	1.205 (0.850-1.708)	0.295